GGrantIndex
← Leaderboards

Joseph J. Eron

Univ Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$450,672,292
Attributed
$847,550,119
Total exposure
76
Grants
35
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $225.5M · FY2005–25
$250M$187.5M$125M$62.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$857,810,348 · 77

By mechanism

UM1$790,236,093 · 2
U01$32,071,382 · 2
M01$27,436,177 · 66
P30$7,084,088 · 5
P01$982,608 · 2

Top collaborators

Most similar at Univ Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHiv InfectionsHuman SubjectHuman Therapy EvaluationAids TherapyCombination ChemotherapyDrug Screening /EvaluationAntiaids AgentZidovudineClinical TrialsProtease InhibitorResearch PersonnelLamivudineResourcesLeadershipPreventionFundingUniversitiesLaboratoriesHuman Immunodeficiency VirusComorbidityAntiviral AgentsCollaborationsArea

Grant awards (200)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$36,436,959
UM1 · FY2025 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$4,889,495
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections-A5407 Third Supplement$2,991,790
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections- Small Clinical Trials Unit (SCTU)$2,203,379
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$976,570
UM1 · FY2025 · AI
UNC Center for AIDS Research Core C Clinical$272,739
P30 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$134,778
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$127,198
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$115,333
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$54,841
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$53,686
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$37,674
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$30,996
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$28,251
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$27,666
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$1
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$1
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$38,497,989
UM1 · FY2024 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$3,992,131
UM1 · FY2024 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$2,801,829
UM1 · FY2024 · AI
Evaluating the Relationship Between Age and HIV-1 Persistence$375,973
UM1 · FY2024 · AI
Examining Immune Senescence in PLWH and HCV, utilizing the ACTG BIRTH Cohort samples$370,632
UM1 · FY2024 · AI
UNC Center for AIDS Research Core C Clinical$268,398
P30 · FY2024 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$261,226
UM1 · FY2024 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 Supplement$69,163
UM1 · FY2024 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$76,222,582
UM1 · FY2023 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$39,807,800
UM1 · FY2023 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$4,091,472
UM1 · FY2023 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$2,500,001
UM1 · FY2023 · AI
UNC Center for AIDS Research Core C Clinical$319,544
P30 · FY2023 · AI · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$71,500,000
UM1 · FY2022 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$37,136,690
UM1 · FY2022 · AI
A5418 MPX-TPOXX Study Supplement$17,327,975
UM1 · FY2022 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$10,000,000
UM1 · FY2022 · AI
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$7,007,011
UM1 · FY2022 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$4,360,341
UM1 · FY2022 · AI · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$356,641
UM1 · FY2022 · AI · contact PI
UNC Center for AIDS Research Core C Clinical$312,308
P30 · FY2022 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$44,503,132
UM1 · FY2021 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$40,164,858
UM1 · FY2021 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$20,566,378
UM1 · FY2021 · AI
CoVPN 3502 / ACTIV-2/A5401$19,807,516
UM1 · FY2021 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$5,609,272
UM1 · FY2021 · AI · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit$1,109,294
UM1 · FY2021 · AI · contact PI
UNC Center for AIDS Research Core C Clinical$467,410
P30 · FY2021 · AI · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$181,942,638
UM1 · FY2020 · AI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$36,091,763
UM1 · FY2020 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials$5,246,488
UM1 · FY2020 · AI · contact PI
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19$1,259,902
UM1 · FY2020 · AI
HIV/AIDS Clinical Trials Unit (CTU) COVID-19 Admin Supplement$600,000
UM1 · FY2020 · AI · contact PI
UNC Center for AIDS Research Core C Clinical$310,708
P30 · FY2020 · AI · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$32,273,937
UM1 · FY2019 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials$6,064,003
UM1 · FY2019 · AI · contact PI
UNC Center for AIDS Research Core C Clinical$442,559
P30 · FY2019 · AI · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials$2,873,337
UM1 · FY2018 · AI · contact PI
UNC Center for AIDS Research Core C Clinical$307,537
P30 · FY2018 · AI · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials$3,028,807
UM1 · FY2017 · AI · contact PI
UNC Center for AIDS Research Core C Clinical$302,214
P30 · FY2017 · AI · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials$2,540,071
UM1 · FY2016 · AI · contact PI
UNC Center for AIDS Research Core C Clinical$298,574
P30 · FY2016 · AI · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials$2,665,274
UM1 · FY2015 · AI · contact PI
Clinical Core$368,975
P30 · FY2015 · AI · contact PI
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration and$184,732
P01 · FY2015 · MH · contact PI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials$10,846,231
UM1 · FY2014 · AI · contact PI
Clinical Core$385,814
P30 · FY2014 · AI · contact PI
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration and$200,611
P01 · FY2014 · MH · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$5,018,251
UM1 · FY2013 · AI · contact PI
Clinical Core$330,461
P30 · FY2013 · AI · contact PI
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration and$193,409
P01 · FY2013 · MH · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$3,236,867
UM1 · FY2012 · AI · contact PI
Clinical Core$358,597
P30 · FY2012 · AI · contact PI
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration and$202,353
P01 · FY2012 · MH · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$4,779,318
U01 · FY2011 · AI · contact PI
Clinical Core$345,115
P30 · FY2011 · AI · contact PI
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration and$201,503
P01 · FY2011 · MH · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$5,303,243
U01 · FY2010 · AI · contact PI
CLINICAL CORE$433,405
P30 · FY2010 · AI · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$174,837
U01 · FY2010 · AI · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$110,263
U01 · FY2010 · AI · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$3,370,206
U01 · FY2009 · AI · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$3,036,786
U01 · FY2009 · AI · contact PI
CLINICAL CORE$331,973
P30 · FY2009 · AI · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$2,899,686
U01 · FY2008 · AI · contact PI
CLINICAL CORE$357,226
P30 · FY2008 · AI · contact PI
CLINICAL TRIAL: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED$171,152
M01 · FY2008 · RR · contact PI
CHAVI 001: ACUTE HIV-1 INFECTION PROSPECTIVE COHORT STUDY$104,390
M01 · FY2008 · RR · contact PI
AACTG 5175 - DRUG COMBINATIONS FOR INITIAL TREATMENT OF HIV-1 INFECTED SUBJECTS$21,849
M01 · FY2008 · RR · contact PI
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS WITH ACUTE INFECTIONS:$9,104
M01 · FY2008 · RR · contact PI
MEASURE THE CLEARANCE OR REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+CELLS$8,498
M01 · FY2008 · RR · contact PI
IN VITRO ASSESSMENT OF IMMUNOGENICITY OF AT2 INACTIVATED AUTOLOGOUS VIRIONS$7,283
M01 · FY2008 · RR · contact PI
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$2,427
M01 · FY2008 · RR · contact PI
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)$2,136,814
U01 · FY2007 · AI · contact PI
ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS$319,108
M01 · FY2007 · RR · contact PI
CLINICAL CORE$318,844
P30 · FY2007 · AI · contact PI
LONGITUDINAL ASSESSMENT OF ACUTE HIV INFECTION$126,957
M01 · FY2007 · RR · contact PI
CHAVI 001: ACUTE HIV-1 INFECTION PROSPECTIVE COHORT STUDY$66,337
M01 · FY2007 · RR · contact PI
AACTG 5175 - DRUG COMBINATIONS FOR INITIAL TREATMENT OF HIV-1 INFECTED SUBJECTS$61,763
M01 · FY2007 · RR · contact PI
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS WITH ACUTE INFECTIONS:$61,763
M01 · FY2007 · RR · contact PI
MEASURE THE CLEARANCE OR REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+CELLS$34,313
M01 · FY2007 · RR · contact PI
LAMIVUDINE PLUS STAVUDINE PLUS ABACAVIR PLUS AMPRENAVIR/RITONAVER$13,725
M01 · FY2007 · RR · contact PI
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$12,582
M01 · FY2007 · RR · contact PI
IN VITRO ASSESSMENT OF IMMUNOGENICITY OF AT2 INACTIVATED AUTOLOGOUS VIRIONS$3,431
M01 · FY2007 · RR · contact PI
REGIMEN SIMPLIFICATION TO ATAZANAVIR/RITONAVIR ALONE AS MAINTENANCE$3,431
M01 · FY2007 · RR · contact PI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS$1,917,303
U01 · FY2006 · AI · contact PI
CLINICAL CORE$307,685
P30 · FY2006 · AI · contact PI
ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS$252,661
M01 · FY2006 · RR · contact PI
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS WITH ACUTE INFECTIONS:$66,436
M01 · FY2006 · RR · contact PI
LONGITUDINAL ASSESSMENT OF ACUTE HIV INFECTION$65,431
M01 · FY2006 · RR · contact PI
AACTG 5175 - DRUG COMBINATIONS FOR INITIAL TREATMENT OF HIV-1 INFECTED SUBJECTS$58,383
M01 · FY2006 · RR · contact PI
IN VITRO ASSESSMENT OF IMMUNOGENICITY OF AT2 INACTIVATED AUTOLOGOUS VIRIONS$25,164
M01 · FY2006 · RR · contact PI
IMMUNIZATION STRATEGY WITH ALVAC-HIV VCP1452 IN HIV-1 SUBJECTS$20,133
M01 · FY2006 · RR · contact PI
MEASURE THE CLEARANCE OR REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+CELLS$12,079
M01 · FY2006 · RR · contact PI
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL$11,074
M01 · FY2006 · RR · contact PI
REGIMEN SIMPLIFICATION TO ATAZANAVIR/RITONAVIR ALONE AS MAINTENANCE$10,065
M01 · FY2006 · RR · contact PI
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$1,006
M01 · FY2006 · RR · contact PI
PHENOTYPIC SUSCEPTIBILITY (C12H/IC50) ON ANTIRETROVIRAL RESPONSE TO RITONAVIR$1,006
M01 · FY2006 · RR · contact PI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS$2,078,465
U01 · FY2005 · AI
ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS$190,475
M01 · FY2005 · RR
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS WITH ACUTE INFECTIONS:$79,502
M01 · FY2005 · RR
IMMUNIZATION STRATEGY WITH ALVAC-HIV VCP1452 IN HIV-1 SUBJECTS$50,516
M01 · FY2005 · RR
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL$34,782
M01 · FY2005 · RR
MEASURE THE CLEARANCE OR REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+CELLS$19,048
M01 · FY2005 · RR
TWO REGIMENS UTILIZING A PROTEASE INHIBITOR-SPARING REGIMEN VS NUCLEOSIDE$17,391
M01 · FY2005 · RR
LONGITUDINAL ASSESSMENT OF ACUTE HIV INFECTION$14,907
M01 · FY2005 · RR
PHENOTYPIC SUSCEPTIBILITY (C12H/IC50) ON ANTIRETROVIRAL RESPONSE TO RITONAVIR$6,626
M01 · FY2005 · RR
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$2,484
M01 · FY2005 · RR
LOPINAVIR/RITONAVIR VS GW433908 AND RITONAVIR VS LOPINAVIR/RITONAVIR AND GW433$827
M01 · FY2005 · RR
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS$2,083,770
U01 · FY2004 · AI
ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS$176,658
M01 · FY2004 · RR
IMMUNIZATION STRATEGY WITH ALVAC-HIV VCP1452 IN HIV-1 SUBJECTS$121,997
M01 · FY2004 · RR
Lopinavir/Ritonavir vs GW433908 and Ritonavir vs Lopinavir/Ritonavir and GW433$53,076
M01 · FY2004 · RR
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$48,323
M01 · FY2004 · RR
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL$48,323
M01 · FY2004 · RR
Treatment of HIV with Stavudine, Didanosine, and Nevirapine$45,946
M01 · FY2004 · RR
Two Regimens Utilizing a Protease Inhibitor-Sparing Regimen vs. Nucleoside$29,310
M01 · FY2004 · RR
ACTG 372: Virologic Success/Options for Virologic Failure in HIV$16,636
M01 · FY2004 · RR
PHENOTYPIC SUSCEPTIBILITY (C12H/IC50) ON ANTIRETROVIRAL RESPONSE TO RITONAVIR$12,674
M01 · FY2004 · RR
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS WITH ACUTE INFECTIONS:$5,545
M01 · FY2004 · RR
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS$2,086,388
U01 · FY2003 · AI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS$2,094,303
U01 · FY2002 · AI
INTRASUBJECT VARIABILITY OF EXCRETION OF HIV IN VAGINAL SECRETIONS$190,747
M01 · FY2002 · RR
COMPARISON OF VIROLOGIC EFFICACY OF NELFINAVIR AND/OR DMP-266$190,747
M01 · FY2002 · RR
EPIVIR, RETROVIR AND PROTEASE INHIBITOR VERSUS 3TC WITH PROTEASE INHIBITOR$190,747
M01 · FY2002 · RR
HYDROXYUREA ALONE &IN COMBINATION W/ DDI VS DDI IN PATIENTS WITH HIV INFECTION$190,747
M01 · FY2002 · RR
STUDY OF VIRACEPT IN COMBINATION WITH ZDV + 3TC VS AZT + 3TC IN HIV PATIENTS$190,747
M01 · FY2002 · RR
THREE FIXED DOSES OF DELAVIRDINE WITH ZDV VS ZDV ALONE IN HIV INFECTION$190,747
M01 · FY2002 · RR
MK639 ADMINISTERED IN COMBINATION WITH ZIDOVUDINE &3TC VS ZDV &3TC VS MK639$190,747
M01 · FY2002 · RR
L-735,524 AND ZIDOVUDINE VS L-735,524 VS ZIDOVUDINE IN HIV INFECTION$190,747
M01 · FY2002 · RR
SOFT GELATIN CAPSULE OF SQVSGC IN COMBINATION WITH RITONAVIR OR NELFIN$190,747
M01 · FY2002 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE$190,747
M01 · FY2002 · RR
VIROLOGIC SUCCESS/OPTIONS FOR VIROLOGIC FAILURE IN HIV$190,747
M01 · FY2002 · RR
PLASMA PHARMACOKINETICS, &ANTIVIRAL ACTIVITY OF T 20 IN HIV$190,747
M01 · FY2002 · RR
141W94/VX-478 PLUS 3TC PLUS ZDV OR INDINAVIR PLUS NEVIRAPINE PLUS 3TC IN HIV$190,747
M01 · FY2002 · RR
ABT378/RITONAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS IN HIV$190,747
M01 · FY2002 · RR
ABT378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$190,747
M01 · FY2002 · RR
LONG TERM SAFETY PROFILE OF 141W94 IN HIV SUBJECTS$190,747
M01 · FY2002 · RR
ZERIT PLUS VIDEX VERSUS RETROVIR PLUS EPIVIR IN HIV SEROPOSITIVE SUBJECTS$190,747
M01 · FY2002 · RR
HIV 1 INFECTED SUBJECTS RESPONSE TO COMBINATIONS OF DDI &HYDROXYUREA$190,747
M01 · FY2002 · RR
ZDV RESISTANT HIV VIRUS IN WOMEN AND EVALUATION OF LONG TERM EFFECTIVENESS$190,747
M01 · FY2002 · RR
PHASE I/II SCREENING TRIAL TO IDENTIFY POTENTIAL PARTNER COMPOUNDS$190,747
M01 · FY2002 · RR
FOUR DRUG REGIMEN VS THREE DRUG REGIMEN IN HIV INFECTED SUBJECTS$190,747
M01 · FY2002 · RR
STUDY OF 141W94/VX-478 MONOTHERAPY VERSUS 141W9/VX$190,747
M01 · FY2002 · RR
T 20 ADMINISTERED TO HIV 1 ADULTS BY CONTINUOUS SUBCUTANEOUS INFUSION$190,747
M01 · FY2002 · RR
COMBINATION THERAPY W/ 1592U89, 141W94, &DMP 266 IN HIV$190,747
M01 · FY2002 · RR
ZIDOVUDINE, LAMIVUDINE AND INDINAVIR IN HIV PATIENTS$190,747
M01 · FY2002 · RR
STUDY OF INDINAVIR SULFATE (IDV) AND 1592689 IN HIV INFECTION$190,747
M01 · FY2002 · RR
DELAVIRDINE MESYLATE IN TRIPLE &QUADRUPLE COMBINATIONS IN HIV 1$190,747
M01 · FY2002 · RR
TREATMENT OF HIV W/ STAVUDINE, DIDANOSINE, &NEVIRAPINE$190,747
M01 · FY2002 · RR
INTRASUBJECT VARIABILITY OF EXCRETION OF HIV IN SEMEN OVER TIME$190,747
M01 · FY2002 · RR
Phase I/II study of a VRP vaccine$0
P01 · FY2002 · AI
T 20 ADMINISTERED TO HIV 1 ADULTS BY CONTINUOUS SUBCUTANEOUS INFUSION$294,555
M01 · FY2001 · RR
L-735,524 AND ZIDOVUDINE VS L-735,524 VS ZIDOVUDINE IN HIV INFECTION$294,555
M01 · FY2001 · RR
MK639 ADMINISTERED IN COMBINATION WITH ZIDOVUDINE &3TC VS ZDV &3TC VS MK639$294,555
M01 · FY2001 · RR
THREE FIXED DOSES OF DELAVIRDINE WITH ZDV VS ZDV ALONE IN HIV INFECTION$294,555
M01 · FY2001 · RR
STUDY OF VIRACEPT IN COMBINATION WITH ZDV + 3TC VS AZT + 3TC IN HIV PATIENTS$294,555
M01 · FY2001 · RR
HYDROXYUREA ALONE &IN COMBINATION W/ DDI VS DDI IN PATIENTS WITH HIV INFECTION$294,555
M01 · FY2001 · RR
EPIVIR, RETROVIR AND PROTEASE INHIBITOR VERSUS 3TC WITH PROTEASE INHIBITOR$294,555
M01 · FY2001 · RR
COMPARISON OF VIROLOGIC EFFICACY OF NELFINAVIR AND/OR DMP-266$294,555
M01 · FY2001 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE$294,555
M01 · FY2001 · RR
SOFT GELATIN CAPSULE OF SQVSGC IN COMBINATION WITH RITONAVIR OR NELFIN$294,555
M01 · FY2001 · RR
VIROLOGIC SUCCESS/OPTIONS FOR VIROLOGIC FAILURE IN HIV$294,555
M01 · FY2001 · RR
141W94/VX-478 PLUS 3TC PLUS ZDV OR INDINAVIR PLUS NEVIRAPINE PLUS 3TC IN HIV$294,555
M01 · FY2001 · RR
ABT378/RITONAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS IN HIV$294,555
M01 · FY2001 · RR
ZERIT PLUS VIDEX VERSUS RETROVIR PLUS EPIVIR IN HIV SEROPOSITIVE SUBJECTS$294,555
M01 · FY2001 · RR
ZDV RESISTANT HIV VIRUS IN WOMEN AND EVALUATION OF LONG TERM EFFECTIVENESS$294,555
M01 · FY2001 · RR
PHASE I/II SCREENING TRIAL TO IDENTIFY POTENTIAL PARTNER COMPOUNDS$294,555
M01 · FY2001 · RR
STUDY OF 141W94/VX-478 MONOTHERAPY VERSUS 141W9/VX$294,555
M01 · FY2001 · RR
ZIDOVUDINE, LAMIVUDINE AND INDINAVIR IN HIV PATIENTS$294,555
M01 · FY2001 · RR
STUDY OF INDINAVIR SULFATE (IDV) AND 1592689 IN HIV INFECTION$294,555
M01 · FY2001 · RR
INTRASUBJECT VARIABILITY OF EXCRETION OF HIV IN SEMEN OVER TIME$294,555
M01 · FY2001 · RR
INTRASUBJECT VARIABILITY OF EXCRETION OF HIV IN VAGINAL SECRETIONS$294,555
M01 · FY2001 · RR
TREATMENT OF HIV W/ STAVUDINE, DIDANOSINE, &NEVIRAPINE$294,555
M01 · FY2001 · RR
DELAVIRDINE MESYLATE IN TRIPLE &QUADRUPLE COMBINATIONS IN HIV 1$294,555
M01 · FY2001 · RR
COMBINATION THERAPY W/ 1592U89, 141W94, &DMP 266 IN HIV$294,555
M01 · FY2001 · RR
FOUR DRUG REGIMEN VS THREE DRUG REGIMEN IN HIV INFECTED SUBJECTS$294,555
M01 · FY2001 · RR
HIV 1 INFECTED SUBJECTS RESPONSE TO COMBINATIONS OF DDI &HYDROXYUREA$294,555
M01 · FY2001 · RR
LONG TERM SAFETY PROFILE OF 141W94 IN HIV SUBJECTS$294,555
M01 · FY2001 · RR
ABT378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$294,555
M01 · FY2001 · RR
PLASMA PHARMACOKINETICS, &ANTIVIRAL ACTIVITY OF T 20 IN HIV$294,555
M01 · FY2001 · RR
LONG TERM SAFETY PROFILE OF 141W94 IN HIV SUBJECTS$190,747
M01 · FY2001 · RR